News | Heart Valve Technology | October 10, 2016

University Hospital Zurich Heart Team First to Perform Tricuspid Valve Repair with Cardioband

Device has traditionally been used for mitral valve repairs

Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano

October 10, 2016 — Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and cardiologists in for the first time repairing a leaky tricuspid valve using a new catheter technology.

Maisano, who is also director of the Clinic for Cardiovascular Surgery at USZ, co-director of the University Heart Center and professor at the University of Zurich, began using the Cardioband in Switzerland for repair of the mitral valve. Now he and his team have succeeded in an application at a leaky tricuspid a 75-year-old patient. The patient is doing well. 

The device has been used previously as a patient-friendly method of repairing a leaking mitral valve in the left heart. It is the minimally invasive alternative to open-heart surgery. Maisano was instrumental in the development of Cardioband, which can be gathered with the help of the leaky valve ring and contracted. For this, the band is placed using a catheter around the valve ring (annulus), and is fixed there by small screws and contracted with a wire, so that the flap closes again tightly.

The tricuspid valve separates the right atrium from the right chamber of the heart. A tricuspid regurgitation, i.e. an insufficient performance of the door, can cause serious symptoms. The backflow of blood into the ventricle and in the veins occur and can cause elevated pressure. This can result in problems in the legs and in the abdomen and liver damage. Also, atrial fibrillation may be associated with the consequences of tricuspid regurgitation. The current treatment of insufficiency of the tricuspid valve consisted of a surgical open-heart surgery using a heart-lung machine. 

Maisano explained the advantages of the new Cardioband method: "Since the insufficiency of this heart valve is often created as the result of mitral valve disease, open-heart surgery is often risky surgery. The use of the Cardioband minimally invasive therapy without the use of cardiopulmonary bypass protects the patient and reduces the risk.”

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," and discussion with Rebecca Hahn, M.D.

For more information: www.valtechcardio.com


Related Content

News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its ...

Home November 20, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
News | Heart Valve Technology

October 17, 2023 — The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone ...

Home October 17, 2023
Home
Subscribe Now